



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

08/482,283 06/07/95 THOMPSON R 04189.0083-0

EXAMINER

HM12/1102

M PAUL BARKER
FINNEGAN HENDERSON FARABOW
GARRETT & DUNNINR
1300 I STREET NW
WASHINGTON DC 20005

SPECIETAL PAPER NUMBER

1647 28
DATE MAILED:

11/02/00

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

Responsive to communication(s) filed on 8/8/00

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 8 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 1,17-25,37-40 is/are pending in the application.

Of the above, claim(s) 1,17-21 remain is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) 22-25,37-40 is/are rejected.

Claim(s) _____ is/are objected to.

Claims 1,17-25,37-40 even are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- Notice of Reference Cited, PTO-892
- Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- Interview Summary, PTO-413
- Notice of Draftsperson's Patent Drawing Review, PTO-948
- Notice of Informal Patent Application, PTO-152

-- SEE OFFICE ACTION ON THE FOLLOWING PAGES --

Part III: Detailed Office Action

Notice: Effective June 18, 2000, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1647.

5

Claims 22-25 and 37-40 are under consideration.

All previous rejections under 35 U.S.C. §112, first paragraph for new matter are withdrawn in view of applicant's amendments and arguments.

10

Formal Matters:

The Information Disclosure Statement filed 12/14/99 has still not been completely considered as the references are missing. Applicants enclosure of the stamped receipt for 133 references is noted, however that does not actually make the references available to the Examiner, nor can the Examiner locate the references in any related file.

15

Drawings

The drawings are objected to as failing to comply with 37 C.F.R. § 1.84(p)(5) because they include the following reference sign(s) not mentioned in the description: In Figure 6 and Figure 7, the chromatographic peaks are given number 1-18 and 1-7, respectively, but these reference numbers are not mentioned in the description. Correction is required.

20

The drawings are objected to because in Figure 4A, the text is upside down. Correction is required.

25

Figures 4, 13, and 15 of the instant application are presented on multiple separate panels. 37 C.F.R. § 1.84 (u)(1) states that when partial views of a drawing which are intended to form one complete view, whether contained on one or several sheets, must be identified by the same number

followed by a capital letter. Applicant is reminded that once the drawings are changed to meet the separate numbering requirement of 37 C.F.R. § 1.84 (u)(1), Applicant is required to change the Brief Description of the Drawings and the rest of the specification accordingly (see p. 42, line 20; p. 17, line 8; p. 18, line 17; and p. 18, line 24). If, for example, Figure 4 is divided into Figures 4A and 4B, then the Brief Description and all references to this figure in the specification must refer to Figures 4A and/or 4B. While all drawings except are correctly numbered, e.g., Figure 4A, Figure 4B, the description of the drawings does not correspond.

Oath/Declaration

10 The oath or declaration is defective. A new oath or declaration in compliance with 37 C.F.R. § 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

15 The oath or declaration is defective because:

Non-initialed alterations have been made to the oath or declaration. See 37 C.F.R. § 1.52(c) and 1.57).

The Residence and Country of Citizenship of inventor R.C. Thompson have been altered without initialing.

20 **Double Patenting Rejections:**

25 The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

30 A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application.

Serial Number 08/482283
Art Unit 1647

See 37 C.F.R. § 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 C.F.R. § 3.73(b).

Claim 22 remains, and newly introduced claims 37-39 are rejected under the judicially created doctrine of double patenting over claim 1 in view of 4 of prior U.S. Patent No. 5,075,222, since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent for reasons cited in the previous Office Action, mailed 1/30/98 , at page(s) 4.

All over 1-31 of 5,075,222 Applicants intent to file a terminal disclaimer to overcome this rejection is noted.

Claims 23-25 remain, and claim 40 is rejected under the judicially created doctrine of double patenting over claims 11 and 17 of U. S. Patent No. 5, 075,222, since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent for reasons cited in the previous Office Action, mailed 1/30/98 , at page(s) 4-5. It is noted that claim 4 of the patent states that the DNA includes nucleotides 99-554 of the sequence listed therein; that sequence plus a methionine codon (or the additional two bases of one), which would be obvious to include as a person of ordinary skill in the art would have known that such is required for translation (production) of the encoded protein, would meet the limitations of claim 40.

Applicants intent to file a terminal disclaimer to overcome this rejection is noted.

+ 95-98 100-101, 106-115, 118, 119, 124-131, 136
Claims 24 and 25 remain rejected under the judicially created doctrine of double patenting over claim 1 of U. S. Patent No. 5,453, 490 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent for reasons cited in the previous Office Action, mailed 1/30/98 , at page(s) 5-6.

Applicants intent to file a terminal disclaimer to overcome this rejection is noted.

Serial Number 08/482283
Art Unit 1647

Advisory Information:

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

5 A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
10
15


Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Lorraine M. Spector, whose telephone number is (703) 308-1793. Dr. Spector can normally be reached Monday through Friday, 8:00 A.M. to 4:30 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, Ph.D., can be reached at (703) 308-4623.

20 Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist at telephone number (703) 308-0196.

25 Certain papers related to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

30 Official papers filed by fax should be directed to (703) 305-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Please advise the Examiner at the telephone number above when an informal fax is being transmitted.

35 
Lorraine Spector, Ph.D.

Primary Examiner

LMS
482283.4
11/1/00